We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
+$163M
Cap. Flow
-$639M
Cap. Flow %
-24.64%
Top 10 Hldgs %
35.1%
Holding
118
New
11
Increased
13
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$84.6M
2
MCK icon
McKesson
MCK
+$33.5M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$32.2M
4
LOXO
Loxo Oncology, Inc
LOXO
+$20.7M
5
BHC icon
Bausch Health
BHC
+$20.6M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$102M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$61.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$46.5M
4
NVRO
NEVRO CORP.
NVRO
+$31.5M
5
HUM icon
Humana
HUM
+$26.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.12%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$17.1B
$26M 1%
929,226
-120,774
-12% -$3.05M
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.36B
$25.9M 1%
3,085,236
-152,498
-5% -$1.06M
SYRS
28
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$25.7M 0.99%
161,514
-19,764
-11% -$2.41M
EPZM
29
DELISTED
Epizyme, Inc
EPZM
$24.2M 0.94%
1,413,596
-187,453
-12% -$2.5M
BOLD
30
DELISTED
Audentes Therapeutics, Inc
BOLD
$23.9M 0.92%
1,403,653
– –
ANAB icon
31
AnaptysBio
ANAB
$1.72B
$23.5M 0.91%
+845,746
New +$19.7M
LKFT
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$22.4M 0.86%
259,768
-163,344
-39% -$11.8M
AAAP
33
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$20.8M 0.8%
523,023
+313,023
+149% +$10.8M
AXGN icon
34
Axogen
AXGN
$2.12B
$19.2M 0.74%
1,838,225
– –
SCTL
35
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$18.1M 0.7%
2,313,625
– –
VTRS icon
36
CALL
Viatris
VTRS
$20.1B
$17.5M 0.68%
450,000
– –
AAC
37
DELISTED
AAC Holdings
AAC
$16.9M 0.65%
1,975,347
– –
BHC icon
38
Bausch Health
BHC
$1.8B
$16.5M 0.64%
+1,500,000
New +$20.6M
CTMX icon
39
CytomX Therapeutics
CTMX
$788M
$16.3M 0.63%
943,433
– –
RNAC icon
40
Cartesian Therapeutics
RNAC
$243M
$15.2M 0.59%
35,333
+6,893
+24% +$2.9M
NEOS
41
DELISTED
Neos Therapeutics, Inc
NEOS
$15.1M 0.58%
2,099,166
+1,870,000
+816% +$11.6M
ONCE
42
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$15.1M 0.58%
283,000
– –
HUM icon
43
Humana
HUM
$48B
$14.3M 0.55%
69,185
-128,815
-65% -$26.6M
IVTY
44
DELISTED
Invuity, Inc
IVTY
$13.4M 0.52%
1,690,498
– –
WVE icon
45
Wave Life Sciences
WVE
$1.12B
$13M 0.5%
472,124
– –
AKTX
46
Akari Therapeutics
AKTX
$19.3M
$12.7M 0.49%
1,438
– –
ACRS icon
47
Aclaris Therapeutics
ACRS
$793M
$11.2M 0.43%
375,000
– –
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.9M 0.42%
933,103
– –
ARDX icon
49
Ardelyx
ARDX
$1.28B
$10.6M 0.41%
841,744
+468,101
+125% +$6.16M
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10.3M 0.4%
+468,867
New +$9.93M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2017 Portfolio in Review

As of Q1 2017, Deerfield Management held 118 positions worth $2.59B, up 6.7% from $2.43B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $639M in Q1 2017, closing 12 positions and reducing 28 holdings. Its most notable exit was Zimmer Biomet, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 69% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $81.7M.

  • Deerfield Management's largest Q1 2017 buy was Gilead Sciences: 1,203,000 shares worth $81.7M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $32.2M increase.
  • Deerfield Management's biggest Q1 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $102M.
  • Deerfield Management fully exited Zimmer Biomet in Q1 2017, selling an estimated $15.5M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.59B portfolio in Q1 2017.
  • Deerfield Management opened 11 new positions and closed 12 in Q1 2017.
  • Deerfield Management's portfolio value rose 6.7% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.